809 results
The study will be performed in 2 parts, Parts 1 and Part 2. The purpose of this study is to investigate to what extent RO6836191 is tolerated. It will also be investigated how quickly and to what extent RO6836191 is absorbed and eliminated from the…
Should low-dose aspirin be continued up until the day of CABG or OPCAB surgery?Should TxA be used for all at-risk CABG or OPCAB surgery?
To compare the safety, effectiveness and performance of TM ABSORB bioabsorbable everolimus eluting vascular scaffold against XIENCE PRIME TM everolimus eluting coronary stent system in treating people with ischemic heart disease caused by de novo…
To understand why statins are able to decrease the risk of developing venous thrombosis, by analyzing whether statins can influence pathways that inhibit coagulation.
Identify congenital heart disease patients with exercise-induced pulmonary arterial hypertension. Analyze changes in pulmonary arterial pressures at peak exercise in patients with exercise induced pulmonary arterial hypertension before and after…
The primary objective is to determine whether additional treatment with exenatide in patients with acute myocardial infarction and treated with primary PCI, leads to a more preserved left ventricular function, compared to placebo in addition to…
- To assess whether a disease specific educational website improves self-care behaviour and quality of life of patients with HF as compared to usual care.- To assess whether a disease-specific educational website plus an interactive web-based…
The study objective is to assess the safety and efficacy of the Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS) compared to the Resolute IntegrityTM Drug-Eluting Stent in patients with single, de novo coronary artery lesions.
Primary objective of the study is• To investigate efficacy and safety of different oraldoses of BAY94-8862 given once daily over 90 daysThe secondary objectives are:•To assess the effects of these doses on a compositeendpoint of death from any cause…
The current study is being conducted to determine whether long-term dual-antiplatelet therapy with ticagrelor in combination with ASA (recommended daily dose 75-100 mg) is beneficial in patients with history of MI (1-3 years ago) and additional risk…
Effectiveness: To provide valid scientific evidence that use of the TactiCath® Set is an effective treatment for symptomatic paroxysmal atrial fibrillation (PAF).Safety: To provide valid scientific evidence that use of the TactiCath® Set is safe as…
To test the hypothesis that 6 months DAPT after second generation DES implantation in STEMI is not inferior to 12 months DAPT in terms of clinical outcomes (composite endpoint of all-cause mortality, any MI, any revascularization, stroke and major…
The primary objectives of this study are to test if aliskiren monotherapy is superior or at least non-inferior to enalapril monotherapy (in the entire study population) and/or to test if aliskiren/enalapril combination is superior to enalapril…
The efficacy of PRDN will be evaluated primarily using echocardiographic parameters. Also, safety of PRDN on major and minor adverse events, LV mass, LV and LA dimensions, MIBG uptake and clinical endpoints will be evaluated. The results of the…
Primary ObjectiveThe primary objective of this study is to compare prospectively in patients treated with TCZ or etanercept (ETA), the time to first occurrence of any component of a composite of major adverse cardiovascular events (MACE) consisting…
- To determine the effects of the pacing site on prevention of AF episodes - To examine the relation between the pacing site, reduction of AF episodes, quality of life, heart failure, number of cardioversions, frequency and duration of hospital…
Primary research questions To investigate whether the outcome after the randomized implantation of the Resolute Integrity® versus Promus Element® drug-eluting stent are similar, as assessed in a non-inferiority setting by comparing target-vessel…
Primary objective: To investigate the safety, tolerability and pharmacokinetics of escalating single doses of MDCO-216 in healthy volunteers and in patients with known stable coronary artery disease.Secondary objective: To characterize the…
The primary objective of this study is to determine whether the Impella cVAD device vs. IABP therapy leads to a higher 30 day survival rate in shock STEMI patients in the setting of primary PCI.
The primary objective of this phase III study is to demonstrate that lixisenatide can reduce cardiovascularmorbidity and mortality (composite endpoint of cardiovascular (CV) death, non-fatal myocardialinfarction (MI), non-fatal stroke,…